Resources

FDA posted five warning letters this week, including several from the Center for Tobacco. None are drug or device GMP warning letters. Now for the interesting part, two warning letters that we cover below were identified as posted on July 23rd. I think this may not be the case because I follow these so closely. So, for any of […]

This week FDA posted three GMP warning letters to drug facilities. We also cover a warning letter to an unapproved, misbranded new drug because of the product category. UNAPPROVED NEW DRUGS | Curaleaf, Inc Curaleaf, Inc (Wakefield, MA) received a warning letter based on evaluation of information on the firm’s website. We generally do not cover warning […]

In June of 2019, we added the following 483s to our database of 27,500+ FDA inspection documents. You can obtain 483s, EIRs, InspectorProfiles, and more at the FDAzilla store. This post is no longer available.

FDA published three drug warning letters this week, one of which was issued in April. The warning letter to Strides Pharma Science Limited revealed the firm to be shredding GMP documents. Fundamental stuff here. Also, Indoco Remedies announced that their solid oral dosage form plant in Goa, India received a warning letter based on an inspection […]

There were six warning letter postings during this week: three drug warning letters including one regarding Akorn’s site in Somerset, NJ that the company announced a few weeks ago, one to a device manufacturer, one to an IRB, and one to a compounding pharmacy. DRUGS | Akorn, Inc. Akorn, Inc. received a warning letter dated […]

A surprisingly busy week for enforcement considering the federal holiday. Warning letter enforcement includes five drug warning letters published this week, two of which were sent to API re-packagers, and one to a compounding pharmacy. API re-packagers have been a focus recently for actions most notably for failure to identify the original manufacturer on the CoA that […]

Three warning letters were posted this week in the areas we cover: two for drugs and one for device GMP violations. The two drug warning letters are for non-prescription drug products, one over-the-counter (OTC) and one homeopathic located in China and India, respectively. Akorn announced that they received a warning letter for the inspection last summer […]

When it comes to data integrity, audit recommendations, and corrective actions, the correct data analysis is essential for making informed, impactful decisions. If you are interested in learning how to perform data analysis that you can trust and use to make better decisions, you should check out the KENX GMP University Conference in San Diego […]

Unlike last week, warning letter enforcement is sparse this week with only one drug GMP warning letter, none to compounding pharmacies and none to device firms. DRUGS | Tropical Seas, Inc Tropical Seas, Inc (Holly Hill, FL) received a warning letter on May 15, 2019, based on the outcome of an inspection ending May 30, […]

A quick note to say: Govzilla is hiring! We’re looking for an account manager to report to the Head of Sales. This is a full-time position based anywhere you are. Here are the details… Job brief We are looking for an Account Manager to create long-term, trusting relationships with our customers. The Account Manager’s primary […]